FCS FCIS - CanSino Biologics Joint Sec
| CASBF Stock | USD 3.88 0.12 3.00% |
Insider
FCS FCIS is Joint Sec of CanSino Biologics
| Age | 46 |
| Phone | 400 922 2099 |
| Web | https://www.cansinotech.com |
CanSino Biologics Management Efficiency
The company has return on total asset (ROA) of (0.0207) % which means that it has lost $0.0207 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0111 %, meaning that it generated $0.0111 on every $100 dollars invested by stockholders. CanSino Biologics' management efficiency ratios could be used to measure how well CanSino Biologics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Shayne Laidlaw | Cronos Group | N/A | |
| Michael Detlefsen | Aurora Cannabis | 56 | |
| Julious Grant | Canopy Growth Corp | 56 | |
| Theresa Firestone | Aurora Cannabis | 65 | |
| FCPA FCA | Canopy Growth Corp | 63 | |
| Robbie Madan | SNDL Inc | 45 | |
| Ryan Hellard | SNDL Inc | 36 | |
| Lance Friedmann | Aurora Cannabis | 65 | |
| Thomas Stewart | Canopy Growth Corp | 42 | |
| James Sabia | Canopy Growth Corp | 59 | |
| James Holm | Cronos Group | 42 | |
| Terry Yanofsky | Canopy Growth Corp | N/A | |
| Theresa Yanofsky | Canopy Growth Corp | 63 | |
| Carlos Cortez | Cronos Group | 51 | |
| James Keough | SNDL Inc | 60 | |
| Andrew Stordeur | SNDL Inc | 44 | |
| Thomas Larssen | Aurora Cannabis | N/A | |
| Kevin Gifford | Cronos Group | N/A | |
| John Barnet | Aurora Cannabis | N/A | |
| Jimes Sabia | Canopy Growth Corp | 58 | |
| Jason Green | Canopy Growth Corp | N/A | |
Management Performance
| Return On Equity | 0.0111 | |||
| Return On Asset | -0.0207 |
CanSino Biologics Leadership Team
Elected by the shareholders, the CanSino Biologics' board of directors comprises two types of representatives: CanSino Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CanSino. The board's role is to monitor CanSino Biologics' management team and ensure that shareholders' interests are well served. CanSino Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CanSino Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yonghui Wu, VP Marketing | ||
| Xuefeng Yu, Chairman, CoFounder | ||
| Tao Zhu, Ex CoFounder | ||
| Chunlin Xin, Director Department | ||
| Xi Luo, Chief Officer | ||
| FCS FCIS, Joint Sec | ||
| Dongxu MBA, Exec CoFounder | ||
| Jing Wang, Deputy Officer | ||
| ShouBai Chao, COO Director |
CanSino Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is CanSino Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0111 | |||
| Return On Asset | -0.0207 | |||
| Profit Margin | 0.06 % | |||
| Operating Margin | (0.19) % | |||
| Current Valuation | 3.58 B | |||
| Shares Outstanding | 114.78 M | |||
| Shares Owned By Insiders | 26.70 % | |||
| Shares Owned By Institutions | 38.17 % | |||
| Price To Earning | 19.25 X | |||
| Price To Book | 2.30 X |
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Other Information on Investing in CanSino Pink Sheet
CanSino Biologics financial ratios help investors to determine whether CanSino Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CanSino with respect to the benefits of owning CanSino Biologics security.